TPST - Tempest Therapeutics Inc. Stock Price, Fair Value and News

3.53USD+0.05 (+1.44%)Delayed

Market Summary

USD3.53+0.05

Delayed

1.44%

TPST Stock Price

View Fullscreen

TPST RSI Chart

TPST Valuation

Market Cap

78.3M

Price/Earnings (Trailing)

-2.66

Price/Sales (Trailing)

1.1K

EV/EBITDA

-1.87

Price/Free Cashflow

-2.85

TPST Price/Sales (Trailing)

TPST Profitability

Operating Margin

-494.44%

EBT Margin

-40618.75%

Return on Equity

-110.17%

Return on Assets

-57.15%

Free Cashflow Yield

-35.14%

TPST Fundamentals

TPST Revenue

Revenue (TTM)

72.0K

TPST Earnings

Earnings (TTM)

-29.5M

Earnings Growth (Yr)

17.74%

Earnings Growth (Qtr)

-10.34%

Breaking Down TPST Revenue

Last 7 days

13.9%

Last 30 days

-4.9%

Last 90 days

-5.4%

Trailing 12 Months

105.2%

How does TPST drawdown profile look like?

TPST Financial Health

Current Ratio

4.29

Debt/Equity

0.23

Debt/Cashflow

-4.37

TPST Investor Care

Shares Dilution (1Y)

83.01%

Diluted EPS (TTM)

-1.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	4.0M	2.0M	72.0K	0
2020	0	7.8M	5.9M	0
2018	755.5K	752.5K	5.3M	9.8M
2017	576.0K	471.0K	330.0K	751.5K
2016	567.0K	726.0K	848.0K	659.0K
2015	176.5K	263.0K	349.5K	436.0K
2013	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tempest Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 29, 2022	woiwode thomas	bought	4,999,990	2.36	2,118,640	-
Jan 07, 2022	dubensky thomas w.	bought	9,560	4.78	2,000	president
Jan 06, 2022	whiting samuel	bought	8,168	4.8048	1,700	chief medical officer
Jun 25, 2021	woiwode thomas	acquired	-	-	997,940	-
Jun 25, 2021	woiwode thomas	acquired	-	-	1,171,090	-
Jun 25, 2021	woiwode thomas	acquired	-	-	7,377	-
Jun 25, 2021	dubensky thomas w.	acquired	-	-	111,343	president
Jun 25, 2021	xu stella	acquired	-	-	579,710	-
Jun 25, 2021	lorenzo pierre	acquired	-	-	53.00	corporate controller
Jun 25, 2021	whiting samuel	acquired	-	-	201	chief medical officer

Which funds bought or sold TPST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-43.92	-149,000	147,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-61,341	-	-%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-98.37	-56,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-17.01	710,557	775,249	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-33.36	66,000	74,000	0.01%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,740	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	added	635	436,792	440,946	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	459,386	459,386	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	added	65.1	149,576	156,125	-%
Feb 14, 2024	EAM Investors, LLC	new	-	617,320	617,320	0.11%

Are Funds Buying or Selling TPST?

Are funds buying TPST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TPST

No. of Funds

Unveiling Tempest Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	rock springs capital management lp	0%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	5.2%	997,940	SC 13D/A
Nov 09, 2023	versant venture capital vi, l.p.	7.5%	997,940	SC 13D/A
Feb 14, 2023	rock springs capital management lp	7.83%	823,654	SC 13G/A
Feb 14, 2023	ecor1 capital, llc	9.99%	1,052,810	SC 13G
May 09, 2022	versant venture capital vi, l.p.	9.7%	997,940	SC 13D
Feb 17, 2022	lav regulus ltd	2.2%	153,744	SC 13G
Feb 14, 2022	ikarian capital, llc	0.9%	58,803	SC 13G/A

Recent SEC filings of Tempest Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	ARS	ARS
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Tempest Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Tempest Therapeutics Inc. News

Latest updates

Tempest Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4
Revenue	204.3%	213,000	70,000	66,500	63,000	3,000	3,000	3,000	22,500	42,000	61,500	81,000	67,000	548,500	56,000	84,000	63,000	127,000	197,000	189,000	146,000	316,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	44,000	54,000	112,000	218,000	29,000	274,000	269,000	1,433,000	1,559,000	1,233,000	1,176,000	1,158,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	5,953,000	7,985,000	7,649,000	8,775,000	9,462,000	18,014,000	14,650,000	22,489,000	19,161,000	18,430,000	21,585,000	20,397,000
S&GA Expenses	-10.4%	2,798,000	3,123,000	3,052,000	3,106,000	2,556,000	1,535,000	1,163,000	1,144,000	1,351,000	3,935,000	1,786,000	1,619,000	-	-	-	-	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	1,680,000	2,394,000	2,621,000	3,560,000	4,016,000	4,997,000	5,764,000	4,709,000	4,990,000	5,987,000	5,955,000	4,667,000
EBITDA Margin	0.2%	-377	-378	-381	-387	-14.08	-7.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-16.2%	389,000	464,000	333,000	437,000	276,000	231,000	-	-	-509,000	228,000	224,000	191,000	-272,500	193,000	186,000	182,000	-	162,000	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	4,000	-	-	-	34,000	11,000	13,000	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-5,679,000	-7,703,000	-7,370,000	-8,493,500	-9,356,000	-18,173,000	-14,886,000	-22,659,000	-19,199,000	-18,518,000	-21,683,000	-20,526,000
EBT Margin	0%	-406	-406	-406	-406	-14.51	-7.39	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	2.4%	-8,947,000	-9,168,000	-8,491,000	-8,110,000	-7,058,000	-5,355,000	-5,431,000	-5,229,000	-10,549,000	-7,536,000	-4,846,000	-4,261,000	-	-	-	-	-	-	-	-	-
Net Income Margin	-1.5%	-762	-750	-721	-291	-9.07	-4.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-7.9%	-9,180,000	-8,509,000	-7,110,000	-11,813,000	57,000	-6,324,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	115.1%	52.00	24.00	31.00	37.00	46.00	63.00	71.00	67.00	73.00	67.00	75.00	73.00	23.00	23.00	57.00	68.00	75.00	58.00	68.00	74.00	84.00
Current Assets	228.4%	40.00	12.00	19.00	25.00	33.00	60.00	68.00	63.00	69.00	63.00	70.00	69.00	20.00	20.00	54.00	65.00	71.00	54.00	65.00	73.00	83.00
Cash Equivalents	252.6%	39.00	11.00	18.00	23.00	31.00	43.00	52.00	46.00	52.00	60.00	17.00	52.00	19.00	19.00	28.00	59.00	3.00	48.00	57.00	66.00	74.00
Net PPE	-8.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-
Liabilities	-1.4%	25.00	25.00	26.00	26.00	28.00	36.00	36.00	38.00	37.00	24.00	27.00	37.00	5.00	5.00	12.00	13.00	15.00	14.00	13.00	11.00	11.00
Current Liabilities	26.8%	9.00	7.00	9.00	8.00	7.00	24.00	22.00	21.00	20.00	6.00	10.00	20.00	3.00	3.00	10.00	11.00	13.00	11.00	11.00	9.00	10.00
Long Term Debt	-25.2%	6.00	8.00	7.00	9.00	10.00	12.00	13.00	15.00	15.00	15.00	15.00	15.00	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
LT Debt, Current	100.8%	4.00	2.00	3.00	1.00	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	0.00
LT Debt, Non Current	-25.2%	6.00	8.00	7.00	9.00	10.00	12.00	13.00	15.00	15.00	15.00	15.00	15.00	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shareholder's Equity	-	27.00	-	5.00	11.00	18.00	27.00	35.00	29.00	36.00	44.00	48.00	25.00	33.00	39.00	45.00	55.00	60.00	45.00	55.00	64.00	73.00
Retained Earnings	-4.7%	-165	-157	-150	-143	-135	-126	-117	-108	-100	-92.28	-84.17	-100	-71.76	-71.76	-231	-220	-208	-196	-184	-174	-164
Additional Paid-In Capital	22.6%	192	157	156	154	154	153	153	138	136	136	132	136	3.00	3.00	275	274	267	239	237	236	235
Shares Outstanding	53.9%	22.00	14.00	13.00	11.00	11.00	11.00	12.00	7.00	7.00	7.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00
Float	-	-	-	16.00	-	-	-	22.00	-	-	-	74.00	-	-	-	33.00	-	-	-	124	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.8%	-6,175	-6,487	-6,392	-8,303	-6,479	-9,072	-8,414	-7,107	-7,985	-11,789	127	-6,310	-4,274	-4,622	40.00	-10,161	-11,691	-8,357	-10,573	-10,601	-9,226
Share Based Compensation	94.8%	1,097	563	440	446	428	438	367	328	278	296	411	120	-406	91.00	227	1,080	1,188	1,196	994	939	43.00
Cashflow From Investing	-Infinity%	-7.00	-	-117	-46.00	-356	-108	-95.00	-3.00	-27.00	14.00	-70.00	-14.00	-5.00	-8.00	33.00	-26.00	-33.00	-87.00	1,132	2,976	2,476
Cashflow From Financing	163466.7%	34,349	21.00	1,188	44.00	-4,726	350	14,376	1,403	-9.00	3,167	40,961	14,944	30.00	11.00	28,969	5,589	26,860	121	22.00	-60.00	70,610

TPST Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 17,498,000	$ 22,527,000
General and administrative	11,659,000	12,113,000
Operating loss	(29,157,000)	(34,640,000)
Other income (expense), net:
Interest expense	(1,449,000)	(1,618,000)
Interest income and other income (expense), net	1,115,000	549,000
Other income (expense), net	(334,000)	(1,069,000)
Provision for income taxes	0	0
Net loss	$ (29,491,000)	$ (35,709,000)
Net loss per share of common stock and pre-funded warrants, basic	$ (1.91)	$ (3.09)
Net loss per share of common stock and pre-funded warrants, diluted	$ (1.91)	$ (3.09)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	15,416,203	11,548,907
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	15,416,203	11,548,907

TPST Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,230	$ 31,230
Insurance recovery of legal settlement		450
Prepaid expenses and other current assets	1,133	1,270
Total current assets	40,363	32,950
Property and equipment—net	840	1,060
Operating lease right-of-use assets	9,952	11,650
Other noncurrent assets	448	429
Total assets	51,603	46,089
Current liabilities:
Accounts payable	845	1,108
Accrued legal settlement		450
Accrued expenses	1,673	2,961
Current loan payable (net of discount and issuance costs of $112 and nil, respectively)	4,285
Current operating lease liabilities	952	1,413
Accrued compensation	1,543	1,248
Interest payable	113	97
Total current liabilities	9,411	7,277
Loan payable (net of discount and issuance costs of $454 and $756, respectively)	6,264	10,371
Operating lease liabilities, less current portion	9,160	10,330
Total liabilities	24,835	27,978
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 22,045,255 and 10,518,539 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	22	11
Additional paid-in capital	192,009	153,872
Accumulated deficit	(165,263)	(135,772)
Total stockholders' equity	26,768	18,111
Total liabilities and stockholders' equity	$ 51,603	$ 46,089

About Tempest Therapeutics Inc.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

CEO	Mr. Stephen R. Brady J.D., LLM
WEBSITE	tempesttx.com
INDUSTRY	Biotechnology
EMPLOYEES	19

Tempest Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Tempest Therapeutics Inc.? What does TPST stand for in stocks?

TPST is the stock ticker symbol of Tempest Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tempest Therapeutics Inc. (TPST)?

As of Fri Apr 26 2024, market cap of Tempest Therapeutics Inc. is 78.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TPST stock?

You can check TPST's fair value in chart for subscribers.

What is the fair value of TPST stock?

You can check TPST's fair value in chart for subscribers. The fair value of Tempest Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tempest Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TPST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tempest Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether TPST is over valued or under valued. Whether Tempest Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Tempest Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TPST.

What is Tempest Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TPST's PE ratio (Price to Earnings) is -2.66 and Price to Sales (PS) ratio is 1.15 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TPST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tempest Therapeutics Inc.'s stock?

In the past 10 years, Tempest Therapeutics Inc. has provided -0.082 (multiply by 100 for percentage) rate of return.